Search

Ah Yu Lee

from Fresh Meadows, NY
Age ~86
Get Report
Also known as:
Ah Y Lee, Yu A Lee, Ahyu Yu Lee, Yu Lee Ah, Lee A Yang, Ah-Yu Lee, Yu Lee Ahyu, Lee Ah Yu, Ahyu Yang
Phone and address:
61-46 146Th St, Flushing, NY 11351
(718) 886-2204
Related to:
Shiyang WangChong Y Hu, 69Yu W Wu, 64Ming Lu Yang, 54Sang J Lee, 53Richard Y Lee, 42Stella J Wu, 41Tai Kang LuJun Hu, 38Becky J Romero, 59Kang Wu Zheng, 91Carol K Lam, 52Wenhuan H Hlu, 58Ming Tao Yang, 55Beckyj LuMimi Shon, 49Qi Peng, 52
Connected to:
A Lee, 45Abi A Lee, 31Abigail LeeAbu B Lee, 66Adela C Lee, 64Adelyn S Lee, 39Adrian J Lee, 36Adriane C Lee, 57Aen H Lee, 44Aeren Lee, 33

Ah Lee Phones & Addresses

  • 61-46 146Th St, Flushing, NY 11351 (718) 886-2204
  • 6146 146Th St, Flushing, NY 11351 (718) 886-2204
  • 14015 Holly Ave, Flushing, NY 11355 (718) 886-3928
  • Fresh Meadows, NY

Resumes

Resumes

Ah Lee Photo 1

Registered Nurse

View page
Location:
Bayside, NY
Industry:
Hospital & Health Care
Work:
St Francis Hospital
Registered Nurse
Ophthalmic Consultants of Long Island
Ophthalmic Scribe
Binghamton University Sep 2011 - Dec 2012
Undergraduate Teaching Assistant
Genji Japanese Cuisine Apr 2008 - Aug 2010
Cashier
Education:
New York University 2017 - 2018
Bachelors, Bachelor of Science, Nursing Binghamton University 2009 - 2013
Bachelors, Bachelor of Arts, Chemistry Bayside High School 2005 - 2009
Skills:
Microsoft Office
Microsoft Excel
Powerpoint
Gc Ms
Gas Chromatography
Hplc
Cyclic Voltammetry
Autotitrator
Potentiometry
Ir Spectroscopy
Pcr
Fluorescence Spectrophotometry
Atomic Spectroscopy
Interests:
Health
Languages:
English
Korean
Certifications:
Basic Life Support (Bls)
Advanced Cardiovascular Life Support (Acls)
Pediatric Advanced Life Support
Ah Lee Photo 2

Ah Lee

View page
Ah Lee Photo 3

Ah Lee

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Ah C. Lee
Owner
Pak Car Boutique Corp
Ret Auto/Home Supplies
212 Canal St, New York, NY 10013
(212) 962-6931
Ah Chye Lee
CURRY LEAVES MALAYSIAN RESTAURANT, INC
135-31 40 Rd, Flushing, NY 11354
Ah Pun Lee
BOWERY APPLIANCE INC
144 Bowery St, New York, NY 10013
144 Bowery, New York, NY 10013
Ah Lol Lee
G CONSTRUCTION GROUP INC
133-12 41 Rd #1R, Flushing, NY 11355
41-61 150 St, Flushing, NY 11355
Ah P. Lee
Vice-President
AVC ENTERPRISE INC
Ret Appliances
298 Grand St, New York, NY 10002
(212) 431-1592
Ah P. Lee
Vice-President
CHINATOWN TV INC
Repair Services Electrical Repair Ret Household Appliances
298 Grand St, New York, NY 10002
240 Grand St, New York, NY 10002

Publications

Us Patents

Sumoylation Of Serca2A And Cardiovascular Disease

View page
US Patent:
20190060424, Feb 28, 2019
Filed:
Sep 4, 2018
Appl. No.:
16/121273
Inventors:
- New York NY, US
Chang Won Kho - New York NY, US
Ah Young Lee - New York NY, US
International Classification:
A61K 38/50
C12Q 1/6883
C12N 7/00
C12N 15/86
A61K 48/00
A61K 38/17
A61K 31/7088
G01N 33/573
Abstract:
Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of SERCA2a post-translation modification such as SUMOylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting SERCA2a degradation. Further provided are methods of diagnosing a propensity to develop heart failure comprising determining if a SERCA2a mutant is present or determining the level of expression of SUMO1 in cardiomyocytes. The disclosure also provides methods of screening for therapeutics that modulate the post-translational modification of SERCA2a, such as by modulating post-translational SUMOylation and/or acetylation.

Benzothiazole Or Benzoxazole Compounds As Sumo Activators

View page
US Patent:
20180127407, May 10, 2018
Filed:
Nov 29, 2017
Appl. No.:
15/826238
Inventors:
- New York NY, US
Ah Young Lee - New York NY, US
Changwon Kho - New York NY, US
Roger J. Hajjar - Tenafly NJ, US
International Classification:
C07D 417/12
C07D 413/12
A61K 48/00
A61K 31/4245
C07D 413/04
A61K 31/433
A61K 31/428
Abstract:
Provided are SUMO activators, which can enhance SUMOylation of SERCA2a, which are useful in the treatment of heart failure, cardiovascular diseases, cancer, neurodegenerative disorders, viral infection, bacterial infection, liver disease, inflammation, and other diseases.

Sumoylation Of Serca2A And Cardiovascular Disease

View page
US Patent:
20170014494, Jan 19, 2017
Filed:
Sep 30, 2016
Appl. No.:
15/281269
Inventors:
- New York NY, US
Chang Won Kho - New York NY, US
Ah Young Lee - New York NY, US
International Classification:
A61K 38/50
A61K 48/00
C12Q 1/68
C12N 7/00
G01N 33/573
A61K 38/17
C12N 15/86
Abstract:
Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of SERCA2a post-translation modification such as SUMOylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting SERCA2a degradation. Further provided are methods of diagnosing a propensity to develop heart failure comprising determining if a SERCA2a mutant is present or determining the level of expression of SUMO1 in cardiomyocytes. The disclosure also provides methods of screening for therapeutics that modulate the post-translational modification of SERCA2a, such as by modulating post-translational SUMOylation and/or acetylation.

Sumoylation Of Serca2A And Cardiovascular Disease

View page
US Patent:
20150316551, Nov 5, 2015
Filed:
Jul 13, 2015
Appl. No.:
14/798357
Inventors:
Roger Joseph Hajjar - Tenafly NJ, US
Chang Won Kho - New York NY, US
Ah Young Lee - New York NY, US
Assignee:
Icahn School of Medicine at Mount Sinai - New York NY
International Classification:
G01N 33/573
C12Q 1/68
Abstract:
Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of SERCA2a post-translation modification such as SUMOylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting SERCA2a degradation. Further provided are methods of diagnosing a propensity to develop heart failure comprising determining if a SERCA2a mutant is present or determining the level of expression of SUMO1 in cardiomyocytes. The disclosure also provides methods of screening for therapeutics that modulate the post-translational modification of SERCA2a, such as by modulating post-translational SUMOylation and/or acetylation.

Benzothiazole Or Benzoxazole Compounds As Sumo Activators

View page
US Patent:
20150218148, Aug 6, 2015
Filed:
Aug 29, 2013
Appl. No.:
14/424289
Inventors:
- New York NY, US
Ah Young Lee - New York NY, US
Changwon Kho - New York NY, US
Roger J. Hajjar - Tenafly NJ, US
International Classification:
C07D 417/12
A61K 48/00
A61K 31/4245
C07D 413/12
A61K 31/428
A61K 31/433
Abstract:
Provided are SUMO activators, which can enhance SUMOylation of SERCA2a, which are useful in the treatment of heart failure, cardiovascular diseases, cancer, neurodegenerative disorders, viral infection, bacterial infection, liver disease, inflammation, and other diseases.

Sumoylation Of Serca2A And Cardiovascular Disease

View page
US Patent:
20140234287, Aug 21, 2014
Filed:
Jul 13, 2012
Appl. No.:
14/232105
Inventors:
Roger Joseph Hajjar - Tenafly NJ, US
Chang Won Kho - New York NY, US
Ah Young Lee - New York NY, US
Assignee:
Icahn School of Medicine at Mount Sinai - New York NY
International Classification:
A61K 38/50
G01N 33/573
C12Q 1/68
A61K 38/17
US Classification:
424 946, 514 44 R, 435 76, 435 618, 435 61, 435 613
Abstract:
Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of SERCA2a post-translation modification such as SUMOylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting SERCA2a degradation. Further provided are methods of diagnosing a propensity to develop heart failure comprising determining if a SERCA2a mutant is present or determining the level of expression of SUMO1 in cardiomyocytes. The disclosure also provides methods of screening for therapeutics that modulate the post-translational modification of SERCA2a, such as by modulating post-translational SUMOylation and/or acetylation.
Control profile
Ah Yu Lee from Fresh Meadows, NY, age ~86 Get Report